Louisiana moved a step closer this week to letting terminally ill patients use medical cannabis inside hospital walls, after the Senate Health and Welfare Committee approved SB 270 in a voice vote Wednesday.

The bill’s author, Sen. Katrina Jackson-Andrews (D), framed the legislation in direct terms. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” she said ahead of the vote.

The proposal targets a gap that has left some of Louisiana’s most vulnerable patients in an awkward position. The state has permitted medical cannabis since 2015 and has steadily expanded its program over the past decade, yet hospital policy and federal funding concerns have kept the medicine off the table in inpatient settings, even for patients with no curative options left.

Under SB 270, hospitals would be required to draft written guidelines permitting covered patients to consume medical cannabis on-site. The legislation restricts allowable consumption forms to non-combustible, non-vaporized products, ruling out smoking and vaping inside facilities. That restriction tracks with standard hospital policies around respiratory irritants and aligns with the product formats most Louisiana dispensaries already emphasize, including tinctures, oils, and edibles.

An amendment adopted by the committee, developed with input from the Louisiana Hospital Association, shapes how the policy would work in practice. Emergency departments and outpatient units are exempted, narrowing the bill’s scope to inpatient care for qualifying patients. The language also puts clear responsibility on the patient and primary caregiver. They must acquire the cannabis through the existing state medical program, administer it themselves, and store it in a locked container they provide. Hospital staff are explicitly prohibited from administering, storing, retrieving, or assisting with the cannabis in any way.

That last provision reflects the central tension running through medical cannabis in any federally funded setting. Hospitals that accept Medicare or Medicaid payments operate under federal rules, and cannabis remains a Schedule I controlled substance under federal law. A staff member who handles a patient’s cannabis supply could theoretically expose a facility to federal sanction. By placing all handling responsibility on the patient and caregiver, the bill tries to insulate hospital employees and the institution from direct involvement.

The amendment also builds in a collective opt-out clause. If federal regulators take enforcement action against any Louisiana healthcare facility over on-site cannabis use, all hospitals in the state may suspend compliance, not just the facility directly targeted. That provision gives the Louisiana Hospital Association and its member institutions a cleaner exit ramp if the federal environment shifts, which has been a persistent concern for hospital administrators in states that have tried to expand patient access to cannabis inside clinical settings.

How regulators in Washington would actually respond remains genuinely uncertain. The Drug Enforcement Administration has signaled interest in rescheduling cannabis to Schedule III, a process still grinding through federal review in 2026. A rescheduling would not immediately resolve the legal conflict for hospitals, but it would change the political calculus around enforcement. Louisiana lawmakers appear to be betting that the current federal posture, which has generally avoided targeting state-compliant medical programs, will hold long enough for the policy to take root.

The bill now moves to the full Senate. If it clears that chamber and passes the House, it would join a stack of cannabis-related legislation Louisiana is weighing this session.

The same committee approved a separate bill last week to create a psychedelic-assisted therapy pilot program, funding clinical trials for psilocybin and ibogaine treatments using dollars from opioid settlement accounts. That bill reflects a broader national trend of redirecting opioid settlement funds toward alternative pain and addiction treatments, a category that increasingly includes psychedelic compounds with early clinical evidence behind them.

Separately, Louisiana legislators are also considering a bill to establish an adult-use marijuana legalization pilot program, structured to test the policy before any permanent codification. The pilot framing is a cautious approach, but it signals that legalization advocates in Baton Rouge have enough traction to get the conversation onto the floor.

For patients and families handling terminal diagnoses, the hospital cannabis bill addresses something concrete. A person with a licensed medical cannabis recommendation in Louisiana can currently use their medicine at home, in a hospice setting under certain circumstances, or in other non-hospital environments. But acute care admissions, often unavoidable near the end of life, have created a forced interruption in a treatment regimen that the patient and their physician may have found useful for pain, nausea, or anxiety. SB 270 would close that gap within specific parameters.

The bill does not require hospitals to accommodate cannabis use, though the written guidelines provision creates an affirmative obligation for facilities that do not opt out. How many Louisiana hospitals would implement the policy, and how quickly, depends partly on their federal reimbursement exposure and partly on their own administrative appetite for handling the new rules. The Louisiana Hospital Association’s involvement in shaping the amendment suggests at least some institutions are preparing to engage rather than simply wait.

Marijuana Moment first reported on this development.

The committee vote was unanimous by voice, which gives the full Senate a clear signal of where the chamber’s health-focused members stand heading into floor debate.